Observed Signal · Sep 8, 2026 · Funding · Source: Tech.eu (European Tech & Deals) · Impact: 3/5 · Sentiment: Positive
sci2sci raises €1.2M for AI verification in regulated industries
Berlin-based startup sci2sci has secured €1.2 million in pre-seed funding to advance its technology for organizing and verifying data in regulated industries like biopharma and banking. The round was co-led by Heliad and IBB Ventures, with participation from Robin Capital and Superangels. The company develops a neurosymbolic memory layer that transforms scattered corporate data into self-verifying knowledge. Its flagship product, Integrity Cortex, encodes information as a formal logic system where every claim must cite a literal source, and a symbolic engine verifies citations, flagging hallucinations and inconsistencies. This provides an auditable record compliant with 21 CFR Part 11. VectorCat serves as a data integration layer, connecting information across cloud and laboratory systems. Senior advisor Stephanie Bova, former Corporate VP at Novo Nordisk, has joined sci2sci. The funding will expand the engineering team, deepen customer deployments, and extend products into banking.
Funding for AI infrastructure in regulated industries is relevant to AdTech's data verification and AI-driven processes.
Track Novo Nordisk Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your Polaris7 workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- sci2sci raised €1.2 million in pre-seed funding, co-led by Heliad and IBB Ventures, with participation from Robin Capital and Superangels.
- The flagship product Integrity Cortex uses a formal logic system to verify citations and ensure compliance with 21 CFR Part 11.
- VectorCat serves as a data integration layer connecting information across systems.
- Stephanie Bova, former Corporate VP at Novo Nordisk, joined sci2sci as a senior advisor.
- Funding will be used to expand the engineering team, deepen deployments, and extend into banking.
Connected Companies & Entities
Ontology Mapping & Concepts
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
Biolevate raises €30M Series A for life sciences AI
Biolevate, a Paris-based life sciences AI company, has raised €30 million in Series A funding to scale its enterprise agentic AI platform designed to automate scientific and regulatory workflows. The round was co-led by RAISE France and Orange Ventures, with participation from MSD Global Health Innovation Fund, Station F, and existing investor EQT Ventures. The platform enables life sciences organizations to run thousands of concurrent AI agents, with outputs grounded in source evidence and human oversight, facilitating use in regulated environments. Since its 2024 seed round, Biolevate has expanded to over a dozen enterprise customers, achieving significant efficiency gains in literature reviews and regulatory intelligence. The company is opening a US office in Boston, has doubled headcount, and plans to double again, while also filing patents in Europe.
Cygrid exits stealth with €2.66M for AI identity security
Berlin-based cybersecurity startup Cygrid has emerged from stealth with a €2.66 million pre-Seed funding round. The round was led by Atlantic, with participation from D11Z and angel investors including Boris Gorin (VP Product at Zscaler), Andreas Bermig (CEO of bonify), and Vlad Tropko of AmberVale Capital. Cygrid, founded in January 2026 by Dmitry Kharchenko and Dekel Paz, both former Israeli Military Intelligence, offers an identity-enforcement platform that continuously checks and controls actions taken by AI agents and other identities within enterprises. Unlike traditional IAM tools that grant access at sign-in, Cygrid maps human, non-human, and AI agent identities into a unified intelligence graph, enabling real-time blocking or narrowing of risky actions. The startup already serves 19 design partners across FinTech, e-commerce, and SaaS, with six in production. It aims to become the European alternative to US and Israeli providers in AI identity security.
UK Sovereign AI Fund and Stripe CEO Back Potential Sciences
London-based startup Potential Sciences has raised a multi-million-dollar seed round backed by the UK government's Sovereign AI fund and Stripe CEO Patrick Collison. The company is developing AI infrastructure for scientific drug discovery, using AI, machine learning, and quantum chemistry simulations to model molecular behavior. Its physics-based AI approach aims to reduce the cost of chemical design calculations by up to 100 times. The Sovereign AI fund is also providing compute capacity. Other investors include Twin Path Ventures, Odyssey, Portfolio Ventures, Blue Wire Capital, rule30, Nauta Capital, and Lightfield Equity. The company declined to disclose the exact amount raised or its valuation. Potential Sciences was founded in November 2025 by Hatem Helal, a former Graphcore executive.
Receive all future signals for Novo Nordisk & competitors in your briefing
Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.
